![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for the treatment of hypertension and angina pectoris.
Lead Product(s): Metoprolol Succinate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACTIBLOK IPR 25
Highest Development Status: Approved Product Type: Small molecule
Recipient: Biocon Biologics
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 13, 2024